Marjan Farid - 31 Oct 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Director
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
31 Oct 2022
Net transactions value
$0
Form type
4
Filing time
01 Nov 2022, 16:12:36 UTC
Next filing
02 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (right to buy) Award $0 +1,600 $0.000000 1,600 31 Oct 2022 Common Stock 1,600 $6.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on October 31, 2022 and vests with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025.